SLC5A2 and heart failure: The SOLOIST-WHF trial evaluated sotagliflozin, which is both a SGLT2 and sodium glucose cotransporter 1 (SGLT1) inhibitor in patients hospitalized for worsening heart failure, which interestingly included patients with heart failure symptoms [34].